Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche's Tecentriq, on top of targeted drugs, stalls melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Roche and KeChow Reach a Cooperation Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Vemurafenib

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under this collaboration, KeChow will promote Roche's Zelboraf® in China. Zelboraf® is an oral small molecule, selective BRAF inhibitor indicated for the treatment of patients with BRAF V600 mutation-positive advanced or inoperable melanoma.

            Lead Product(s): Vemurafenib

            Therapeutic Area: Oncology Product Name: Zelboraf

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 20, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            In a phase 3 study presented at the American Association for Cancer Research meeting, adding Tecentriq to the targeted melanoma drugs lowered the risk of disease progression.

            Lead Product(s): Atezolizumab,Cobimetinib,Vemurafenib

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY